QuidelOrtho (QuidelOrtho) Change In Working Capital : $-296 Mil (TTM As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is QuidelOrtho Change In Working Capital?

QuidelOrtho's change in working capital for the quarter that ended in Mar. 2024 was $-86 Mil.

QuidelOrtho's change in working capital for the fiscal year that ended in Dec. 2023 was $-195 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

QuidelOrtho Change In Working Capital Historical Data

The historical data trend for QuidelOrtho's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho Change In Working Capital Chart

QuidelOrtho Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-15.24

-251.07

-2.80

-53.20

-194.90

QuidelOrtho Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															14.40	-95.40	-68.70	-45.20	-86.30

QuidelOrtho Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-296 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

QuidelOrtho Change In Working Capital Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

QuidelOrtho (QuidelOrtho) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

QL1A:Germany

Address

9975 Summers Ridge Road, San Diego, CA, USA, 92121

Website

https://www.quidelortho.com

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make better decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.

Executives

Louise Brandy	officer: SVP, Chief Information Officer	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein	officer: Chief Administrative Officer	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Christopher M Smith	director	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Edward L. Michael	director	618 SHERIDAN SQUARE, EVANSTON IL 60202
William J. Ferenczy	officer: SVP, Cardio/Metabolic Unit	9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Werner Kroll	officer: SVP, Research and Development	12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Kenneth F Buechler	director
Robert R. Schmidt	director	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli	officer: SVP, Molecular Bus. Unit	9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Stephen H. Wise	director	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Robert Joseph Bujarski	officer: See Remarks	C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Wilkins Joseph D Jr.	director	82414 PUCCINI DRIVE, INDIO CA 92203
Michelle A. Hodges	officer: SVP, General Counsel	9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Douglas C Bryant	director, officer: Chairman & CEO	C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Joseph M Busky	officer: Chief Financial Officer	1717 DEERFIELD ROAD, DEERFIELD IL 60015